ROIV Stock Price Today (September 2026) — Roivant Sciences Ltd. Analysis & Key Metrics 2026-09-08
Roivant Sciences Ltd. (ROIV) is trading at $41.48, up 18.75% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $41.86 (0.9% upside).
- Volatility remains elevated (69.78% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (-33.50% YoY) alongside significant competitive pressures.
ROIV Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Roivant Sciences Ltd. - Historical Price & Volume
Market Cap
Enterprise Value: $22.03B
P/E Ratio
Forward P/E: -20.17
Revenue Growth
Year over Year
Analyst Target
+0.9% upside potential
Key Investor Questions About ROIV
What investors need to know before buying
Based on current market data, ROIV presents a overbought technical setup with challenging fundamentals.
- Technicals say: Overbought (RSI 78.79)
- Fundamentals say: Challenging (declining revenue trends)
ROIV's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ROIV investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $107.15M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, ROIV stock traded between $11.94 and $37.97—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 69.78% annualized volatility and β=0.91, the stock exhibits moderate correlation to market moves—making ROIV suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Why Did DELL, ROIV, SHEL Stocks Surge To 52-Week Highs Today?
Investors rewarded three very different catalysts spanning artificial intelligence, biotechnology, and energy.
Roivant (ROIV) Soars to All-Time High; Q2 Hedge Fund Holdings Surge 41%
Roivant Sciences Ltd. (NASDAQ:ROIV) soared to a new all-time high on Tuesday after reporting stellar results from the clinical trial of its treatment candidate for pulmonary hypertension associated with interstitial lung disease (PH-ILD). In intra-day trading, the stock jumped to its highest price of $42.50 before trimming gains to end the session just up by […]
Biotech Stocks, With 'Blowout' And 'Bull Case' Results, Rocket To Record Highs
Biotech stocks Roivant and Pharvaris hit records Tuesday on "blowout" and "bull case" results for lung and swelling disease treatments.
These 2 Biotech Stocks Hit Record Highs Today – What’s Driving The Rallies?
Roivant Sciences reported positive Phase 2 results for its experimental lung disease drug, Mosliciguat, while Pharvaris’ oral therapy met the main goal of a Phase 3 study of preventive treatment for hereditary angioedema.
Top Midday Gainers
Roivant Sciences (ROIV) shares soared 19% after the company said its Pulmovant unit's phase 2 PHocus
Roivant Sciences Stock Soars as Lung Disease Drug Hits Goals
Roivant Sciences stock was surging after the biotech reported success in a mid-stage trial of its experimental lung-and-heart artery drug, mosliciguat.
Roivant Stock Surges on 'Robust' Data from Rare Lung Disease Candidate
Pulmovant, a clinical-stage biotech and Roivant (NASDAQ:ROIV) company, on Tuesday shared topline data from its Phase 2 PHocus clinical trial evaluating mosliciguat for pulmonary hypertension associated with interstitial lung disease (PH-ILD). PH-ILD occurs when scarring and inflammation in the lungs restrict blood flow through the pulmonary arteries, raising blood pressure within the lungs. Presented at the European Respiratory Society International Congress 2026, the data highlight meaningful c
Update: US Equity Futures Mostly Lower as Traders Assess Rising Oil, Canadian Retaliatory Tariffs
(Updates with economic data, recent oil price movement, world markets' overview and corporate stock
Roivant’s Experimental Lung Disease Drug Hits Key Phase 2 Goal – ROIV Stock Tracks All-Time High
Roivant’s Mosliciguat reduced pulmonary vascular resistance by 56.3% compared with placebo after 16 weeks.
Roivant Sciences Shares Rise After Phase 2 Mosliciguat Results
Roivant Sciences (NASDAQ:ROIV) shares rose 22. 0% in premarket trading after its Pulmovant subsidiary reported topline results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease, or PH-ILD.
Explore More Analysis for ROIV
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Roivant Sciences Ltd.
Roivant Sciences Ltd. (ROIV) is currently trading at $41.48. The RSI (14-day) is at 78.8, indicating overbought territory (potentially overheated). Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $41.86 implies 0.9% upside from current levels. Volatility is high at 69.8% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Roivant Sciences Ltd. (ROIV): The trailing P/E ratio is -88.26, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -20.17. Price-to-Book is 7.08. Price-to-Sales is 3977.96. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 11 analysts covering ROIV, the consensus price target is $41.86. This represents a 0.9% upside from the current price of $41.48. The range spans from a low target of $37.50 to a high target of $50.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Roivant Sciences Ltd. (ROIV) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Roivant Sciences Ltd. (ROIV) investors include: 1. High volatility (69.8% annualized)—the stock can experience significant daily price swings. 2. Declining revenue (-33.5% YoY), indicating potential business headwinds. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Roivant Sciences Ltd.'s (ROIV) current debt and financial health profile: Total debt stands at $107.15M. The debt-to-equity ratio is 2.18, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 16.72, indicating strong short-term liquidity. The quick ratio is 13.62. The company holds $3.84B in cash and equivalents. Free cash flow is negative at $-1,127,230,080, which could limit the company's ability to manage debt obligations.